Anisindione

  • Andion
  • Anisin indandione
  • 2-para-Anisyl-1,3-Indandione
  • 2-(b-Methoxyphenyl)-1,3-Indandione
  • 2-(4-Methoxyphenyl)indan-1,3-dione
  • 2-(b-Methoxyphenyl)indane-1,3-dione
Formula
C16H12O3
Structure
Description
Pale yellow crystals from acetic acid or ethanol. Odorless or has slightly sweet odor.
Uses
Medication.

Registry Numbers and Inventories.
CAS
117-37-3
EC (EINECS/ELINCS)
204-186-6
RTECS
NK5775300
RTECS class
Drug
UN (DOT)
1325
Merck
12,706
Beilstein/Gmelin
1880681
Beilstein Reference
3-08-00-02931

Properties.
Formula
C16H12O3
Formula mass
252.27
Melting point, °C
155 - 156
Boiling point, °C
297
Critical temperature
621
Critical pressure
26.3
Solubility in water
Insoluble
pKa/pKb
8.64 (pKa)
Partition coefficient, pKow
2.32

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Wear appropriate protective gloves, clothing and goggles.
Respirators
Wear positive pressure self-contained breathing apparatus (SCBA).
Small spills/leaks
Make no contact with the spilled material. ELIMINATE all ignition sources and ground all equipment. With clean shovel place material into clean, dry container and cover loosely; move containers from spill area.
Stability
Stable in light and air.

Fire.
Fire fighting
Small Fires: Dry chemical, carbon dioxide, sand, earth, water spray or regular foam. Large Fires: Water spray, fog or regular foam.
Fire potential
Flammable/combustible material. May be ignited by friction, heat, sparks or flames.
Combustion products
Fire may produce irritating and/or toxic gases.

Health.
Exposure effects
Intracranial hemorrhage and hematomyelia may occur following warfarin therapy. The use of warfarin during pregnancy has been associated with teratogenic effects. <br>Fetal intraventricular hemorrhage has been reported following maternal ingestion of warfarin. <br>Craniofacial, musculoskeletal, skin, eye, gastrointestinal, and cardiovascular developmental abnormalities have been observed in the offspring of women administered warfarin sodium during pregnancy. <br>Intrauterine fetal demise, intrauterine growth retardation, and hemorrhagic disease of the newborn have been reported following administration of warfarin sodium to pregnant women.
   Ingestion
Abdominal pain, vomiting, gastrointestinal bleeding, hemoptysis, and bloody or melenotic stools may occur.
   Skin
Warfarin may be absorbed through the skin and cause systemic poisoning.
   Eyes
See Skin.

First aid
 
   Ingestion
Seek medical assistance.
   Inhalation
Move victim to fresh air. Apply artificial respiration if victim is not breathing. Administer oxygen if breathing is difficult.
   Skin
Remove and isolate contaminated clothing and shoes. In case of contact with substance, immediately flush with running water for at least 20 minutes. Wash skin with soap and water.
   Eyes
In case of contact with substance, immediately flush with running water for at least 20 minutes.

Transport.
UN number
1325
Response guide
Hazard class
4.1
Packing Group
II; III